Saswati Hazra
YOU?
Author Swipe
View article: Colonic Perforation in Dengue Fever: A Case Series
Colonic Perforation in Dengue Fever: A Case Series Open
Dengue fever is a widespread viral infection endemic in tropical and subtropical regions. While its common manifestations include fever, headache, and musculoskeletal pain, gastrointestinal complications such as colonic perforation are exc…
View article: The New Kid on the Block: Validating the Role of Indocyanine Green for Sentinel Lymph Node Biopsy in the Post-neoadjuvant Setting in Patients With Breast Cancer
The New Kid on the Block: Validating the Role of Indocyanine Green for Sentinel Lymph Node Biopsy in the Post-neoadjuvant Setting in Patients With Breast Cancer Open
Background and objective There is scarce literature on the role of indocyanine green (ICG) in sentinel lymph node biopsy (SLNB) post-neoadjuvant chemotherapy (NACT) in breast cancer patients, specifically in the Indian population. This stu…
View article: Necrotising Soft-tissue Infection of the Breast: Case Series of a Rare but Fatal Entity
Necrotising Soft-tissue Infection of the Breast: Case Series of a Rare but Fatal Entity Open
Necrotising Soft-tissue Infection (NSTI) of the breast is an exceedingly rare but highly aggressive condition that constitutes a true surgical emergency. It leads to extensive tissue necrosis, systemic toxicity and can be fatal if not trea…
View article: Supplementary Table 1 from Loss of miR125a Expression in a Model of K-ras–Dependent Pulmonary Premalignancy
Supplementary Table 1 from Loss of miR125a Expression in a Model of K-ras–Dependent Pulmonary Premalignancy Open
PDF file - 10K, miR-125a expression in human tissue (normal and premalignant atypical adenomatous hyperplasia lesions).
View article: Data from Loss of miR125a Expression in a Model of K-ras–Dependent Pulmonary Premalignancy
Data from Loss of miR125a Expression in a Model of K-ras–Dependent Pulmonary Premalignancy Open
Understanding the molecular pathogenesis of lung cancer is necessary to identify biomarkers/targets specific to individual airway molecular profiles and to identify options for targeted chemoprevention. Herein, we identify mechanisms by wh…
View article: Data from Loss of miR125a Expression in a Model of K-ras–Dependent Pulmonary Premalignancy
Data from Loss of miR125a Expression in a Model of K-ras–Dependent Pulmonary Premalignancy Open
Understanding the molecular pathogenesis of lung cancer is necessary to identify biomarkers/targets specific to individual airway molecular profiles and to identify options for targeted chemoprevention. Herein, we identify mechanisms by wh…
View article: Supplementary Table 1 from Loss of miR125a Expression in a Model of K-ras–Dependent Pulmonary Premalignancy
Supplementary Table 1 from Loss of miR125a Expression in a Model of K-ras–Dependent Pulmonary Premalignancy Open
PDF file - 10K, miR-125a expression in human tissue (normal and premalignant atypical adenomatous hyperplasia lesions).
View article: Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial Open
View article: Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade Open
Background Albumin-bilirubin (ALBI) grade is an objective measure of liver function for patients with hepatocellular carcinoma (HCC). The tyrosine kinase inhibitor cabozantinib is approved for patients with advanced HCC who have received p…
View article: AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario
AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario Open
View article: Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate Cells
Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate Cells Open
Depletion of peroxisome proliferator-activated receptor gamma (PPARgamma) accompanies myofibroblastic transdifferentiation of hepatic stellate cells (HSC), the primary cellular event underlying liver fibrogenesis. The treatment of activate…
View article: Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design Open
Cabozantinib is an oral tyrosine kinase inhibitor that targets VEGFR, MET and the TAM (TYRO3, AXL, MER) family of kinase receptors. In addition to their role in tumor growth and angiogenesis, cabozantinib targets promote an immune-suppress…
View article: PPAR Gamma and Hepatic Stellate Cells
PPAR Gamma and Hepatic Stellate Cells Open
Activation of Hepatic stellate cells (HSC) in fibrogenesis involves distinct morphological and biochemical changes. This activation requires the coordinated changes in activity of several transcription factors. Peroxisome proliferator-acti…
View article: Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy Open